Back to search

Peptide record

TPDB91356

MAC1/16 MAC1/19 MAC1/4 MAC1/6 MAC1 Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity standard

13 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB91356

Peptide_Name

MAC1/16 MAC1/19 MAC1/4 MAC1/6 MAC1

Activity

Antibacterial Anticancer Antifungal Antiparasitic Antiviral Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF pep-lab AFP-GFuse Antifungipept CAFPdb ToxinPred 3.0

Sequence_Type

standard

Has_Modification No

Description A 13-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

GFGMALKLLKKVL-NH2

FASTA

>TPDB91356|Antibacterial;Anticancer;Antifungal;Antiparasitic;Antiviral;Toxicity|length=13
GFGMALKLLKKVL-NH2

Formula C68H120N16O14S1

Absent Amino Acids RNDCEQHIPSTWY

Common Amino Acids L

Mass 1417.86

PI 10.84

Basic Residues 3

Acidic Residues 0

Hydrophobic Residues 8

Net Charge +3

Boman Index -0.71

Hydrophobicity 1.031

Aliphatic Index 150.00

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 0

number

Amino Acid Distribution

A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 0 L: 4 K: 3 M: 1 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 1

Length

Formula

C68H120N16O14S1

Mass

1417.86

10.84

Net Charge

Boman Index

-0.71

Hydrophobicity

1.031

C_terminal_Modification

Amidation

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial and Antifungal

Origin

Macropins and their analogs

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 10±4 µM

Detail Source Activity Anticancer

Activity Measurement 10

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 15±5 µM

Detail Source Activity Anticancer

Activity Measurement 15

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 8±2 µM

Detail Source Activity Anticancer

Activity Measurement 8

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 32±2 µM

Detail Source Activity Anticancer

Activity Measurement 32

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 5 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 21±4 µM

Detail Source Activity Anticancer

Activity Measurement 21

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 23±4 µM

Detail Source Activity Anticancer

Activity Measurement 23

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 7 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 49±9 µM

Detail Source Activity Anticancer

Activity Measurement 49

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 8 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 29±3 µM

Detail Source Activity Anticancer

Activity Measurement 29

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 9 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 > 100 µM

Detail Source Activity Anticancer

Activity Measurement 100 µM

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 10 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 68±2 µM

Detail Source Activity Anticancer

Activity Measurement 68

Target

Cancer Type Colon Cancer

Cell Line SW

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 11 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 12±6 µM

Detail Source Activity Anticancer

Activity Measurement 12

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 12 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 29 µM

Detail Source Activity Anticancer

Activity Measurement 29 µM

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 13 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 15 µM

Detail Source Activity Anticancer

Activity Measurement 15 µM

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 14 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 70 µM

Detail Source Activity Anticancer

Activity Measurement 70 µM

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 15 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 43±11 µM

Detail Source Activity Anticancer

Activity Measurement 43

Target

Cancer Type Leukemia Cancer

Cell Line CCRF-CEM

Tissue Affected Blood

Assay & Model

Assay MTT/MTS assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012